- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Covid-19 Vaccine: Draw up immunization strategy now itself, says Biocon Chief Kiran Mazumdar-Shaw
Bengaluru: India needs to draw up its immunization strategy now itself on the administration of the vaccine for COVID-19 on the population when it comes out, says biotechnology industry veteran Kiran Mazumdar-Shaw.
"Vaccine is anybody's guess. Right from the end of this year to the middle of next year is the prediction", the Executive Chairperson of the city-headquartered biopharmaceuticals major Biocon said on the time-frame vis-a-vis its availability. She said some vaccine programs have just started phase 3 clinical trials, with phase 1 and phase 2 ones having shown mixed signals.
So, we are not sure, she said and, citing reports from the US, added: It looks like every vaccine needs two doses (per person). So, its not cheap", she told here in an interview.
"If the government can make sure that at least 20 percent of the most high-risk population is immunized, then we can sort of creating a control on the virus."
But Mazumdar-Shaw also noted 20 percent of the Indian population is a huge 200 to 300 million people. "Will the government bear it (cost)?", she asked. "So, one has to look at the pharmacoeconomics point of view and immunological rationale and find a balance between the two. Epidemiologists have to work out the model as to what is the minimum number of people who need to be vaccinated when the vaccine comes out. We cannot obviously vaccinate 1.3 billion people (the country's total population) in such a short time because there won't be enough vaccine", she said. Even if the vaccine producers were going to make a billion doses, it cannot be done in one month. "Maximum you can produce is 80 million to 100 million doses per month. So, which are the first 100 million people that will be vaccinated? Those are the kinds of planning we need to do now", she said.
"If the Bharat Biotech vaccine, or Zydus Cadila vaccine starts showing good, promising results, we could also have it (vaccine) by the end of the year", Mazumdar-Shaw said.
On when she expected coronavirus cases to peak in the country, she said there were various forecasts and projections, and each part of the country was at a different level.
"They (forecasts and projections) are basically saying in the next two-and-half-months to four months, various parts of the country should be peaking. By the end of the year, all parts of the country would have peaked. "
"By early December, we should have crossed the peak across the country. Every part of the country will peak at a different time, she said.
Mazumdar-Shaw hastened to add: And then people don't know about the next wave. That is another worry.
As on Monday morning, the country's COVID-19 cases tally stands at 11,18,043 and the death toll reached 27,497.
Read also: Biocon Itolizumab gets DCGI nod to treat COVID-19 patients
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751